Royal Bank of Canada
NAVB

Royal Bank of Canada’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Royal Bank of Canada’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1
Closed – – 8016
2023
Q1 		$0 Buy
+1
New – ﹤0.01% 7872
2020
Q4 		– Sell
-2,000
Closed -$5K – 7538
2020
Q3 		$5K Buy
+2,000
New +$7.18K ﹤0.01% 6161
2019
Q3 		– Sell
-125
Closed – – 7479
2019
Q2 		$0 Hold
125
– – ﹤0.01% 7457
2019
Q1 		$0 Hold
125
– – ﹤0.01% 7328
2018
Q4 		$0 Hold
125
– – ﹤0.01% 7444
2018
Q3 		$1K Hold
125
– – ﹤0.01% 6654
2018
Q2 		$1K Sell
125
-5
-4% -$26 ﹤0.01% 6447
2018
Q1 		$1K Sell
130
-205
-61% -$1.53K ﹤0.01% 6265
2017
Q4 		$2K Sell
335
-200
-37% -$1.69K ﹤0.01% 6334
2017
Q3 		$4K Buy
535
+4
+0.8% +$34 ﹤0.01% 6486
2017
Q2 		$5K Buy
531
+1
+0.2% +$10 ﹤0.01% 6074
2017
Q1 		$6K Hold
530
– – ﹤0.01% 6179
2016
Q4 		$7K Hold
530
– – ﹤0.01% 6231
2016
Q3 		$10K Hold
530
– – ﹤0.01% 5797
2016
Q2 		$6K Hold
530
– – ﹤0.01% 5917
2016
Q1 		$10K Sell
530
-3,887
-88% -$74.8K ﹤0.01% 5745
2015
Q4 		$118K Buy
4,417
+3,535
+401% +$123K ﹤0.01% 4845
2015
Q3 		$40K Sell
882
-101
-10% -$3.81K ﹤0.01% 5253
2015
Q2 		$32K Buy
983
+31
+3% +$901 ﹤0.01% 5458
2015
Q1 		$30K Buy
952
+422
+80% +$14.3K ﹤0.01% 5183
2014
Q4 		$20K Buy
530
+100
+23% +$2.75K ﹤0.01% 5411
2014
Q3 		$11K Sell
430
-10
-2% -$265 ﹤0.01% 5464
2014
Q2 		$13K Sell
440
-551
-56% -$17.8K ﹤0.01% 5336
2014
Q1 		$37K Buy
991
+581
+142% +$22K ﹤0.01% 4985
2013
Q4 		$17K Sell
410
-2,403
-85% -$94K ﹤0.01% 5320
2013
Q3 		$149K Buy
2,813
+2,023
+256% +$118K ﹤0.01% 4258
2013
Q2 		$42K Buy
+790
New +$39.4K ﹤0.01% 4750

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Royal Bank of Canada's NAVB Position: Q2 2023 in Review

Royal Bank of Canada sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 1 share.

Royal Bank of Canada first reported a position in NAVB in Q2 2013 and held it in 27 quarters. The position peaked at $149K in Q3 2013. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Royal Bank of Canada reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Royal Bank of Canada sold 1 Navidea Biopharmaceuticals Inc. share in Q2 2023.
  • Royal Bank of Canada first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 27 quarters.
  • Royal Bank of Canada's Navidea Biopharmaceuticals Inc. position peaked at $149K in Q3 2013.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.